Atea Pharmaceuticals (AVIR) Competitors $3.52 +0.03 (+0.71%) As of 02:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. PHVS, VERV, LENZ, PRAX, RCUS, AVXL, GPCR, SYRE, AKBA, and PHARShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Pharvaris (PHVS), Verve Therapeutics (VERV), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Structure Therapeutics (GPCR), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors Pharvaris Verve Therapeutics LENZ Therapeutics Praxis Precision Medicines Arcus Biosciences Anavex Life Sciences Structure Therapeutics Spyre Therapeutics Akebia Therapeutics Pharming Group Atea Pharmaceuticals (NASDAQ:AVIR) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment. Is AVIR or PHVS more profitable? Atea Pharmaceuticals' return on equity of -32.55% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -32.55% -30.47% Pharvaris N/A -69.09%-63.34% Which has more volatility and risk, AVIR or PHVS? Atea Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.81, meaning that its share price is 381% less volatile than the S&P 500. Do institutionals & insiders believe in AVIR or PHVS? 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 18.1% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, AVIR or PHVS? Pharvaris is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea PharmaceuticalsN/AN/A-$168.38M-$1.61-2.19PharvarisN/AN/A-$145.24M-$3.36-6.52 Do analysts prefer AVIR or PHVS? Atea Pharmaceuticals currently has a consensus target price of $6.00, indicating a potential upside of 70.21%. Pharvaris has a consensus target price of $35.60, indicating a potential upside of 62.59%. Given Atea Pharmaceuticals' higher possible upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer AVIR or PHVS? In the previous week, Pharvaris had 23 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 26 mentions for Pharvaris and 3 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.46 beat Pharvaris' score of 0.36 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAtea Pharmaceuticals beats Pharvaris on 9 of the 13 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$279.74M$3.13B$5.72B$9.77BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-2.1920.9330.9025.26Price / SalesN/A231.60403.8188.28Price / CashN/A41.5625.2228.45Price / Book0.689.749.516.00Net Income-$168.38M-$54.74M$3.26B$265.34M7 Day Performance0.43%7.94%4.48%2.84%1 Month Performance4.91%7.52%5.19%1.58%1 Year Performance-4.21%17.41%31.75%25.40% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals2.2772 of 5 stars$3.53+0.7%$6.00+70.2%-4.9%$279.74MN/A-2.1970PHVSPharvaris2.728 of 5 stars$20.84+3.6%$36.20+73.7%+18.9%$1.05BN/A-6.9230News CoverageEarnings ReportShort Interest ↓Analyst RevisionVERVVerve Therapeutics3.0802 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110LENZLENZ Therapeutics2.0297 of 5 stars$38.77+11.8%$49.60+27.9%+66.4%$989.15MN/A-20.41110Gap UpHigh Trading VolumePRAXPraxis Precision Medicines1.8634 of 5 stars$44.95-2.2%$95.22+111.8%-10.9%$966.84M$8.55M-3.66110RCUSArcus Biosciences2.224 of 5 stars$9.19+1.4%$21.14+130.2%-33.4%$964.27M$258M-2.90500AVXLAnavex Life Sciences3.8231 of 5 stars$11.35+2.4%$44.00+287.7%+63.2%$946.42MN/A-20.6440Earnings ReportGPCRStructure Therapeutics2.3049 of 5 stars$17.51+7.4%$75.71+332.4%-45.8%$939.42MN/A-16.68136News CoverageSYRESpyre Therapeutics2.891 of 5 stars$15.25+0.6%$53.40+250.2%-34.9%$915.68M$890K-4.4973Positive NewsAKBAAkebia Therapeutics3.9694 of 5 stars$3.35-2.0%$6.75+101.5%+125.7%$906.80M$160.18M-19.70430PHARPharming Group2.1478 of 5 stars$12.10-8.5%$30.00+147.9%+50.2%$906.45M$297.20M-93.08280Short Interest ↑Gap DownHigh Trading Volume Related Companies and Tools Related Companies Pharvaris Alternatives Verve Therapeutics Alternatives LENZ Therapeutics Alternatives Praxis Precision Medicines Alternatives Arcus Biosciences Alternatives Anavex Life Sciences Alternatives Structure Therapeutics Alternatives Spyre Therapeutics Alternatives Akebia Therapeutics Alternatives Pharming Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access